DexCom (NASDAQ:DXCM) Price Target Raised to $82.00 at Benchmark

DexCom (NASDAQ:DXCM) had its target price raised by Benchmark from $77.00 to $82.00 in a research report released on Friday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the medical device company’s stock.

DXCM has been the subject of several other research reports. Weiss Ratings cut shares of DexCom from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday. BTIG Research restated a “buy” rating and set a $90.00 target price (up from $80.00) on shares of DexCom in a research report on Friday. Mizuho raised their target price on shares of DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Barclays reiterated an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Finally, Canaccord Genuity Group set a $82.00 price target on DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $88.12.

DexCom Stock Up 12.0%

DXCM stock opened at $83.45 on Friday. DexCom has a fifty-two week low of $54.11 and a fifty-two week high of $87.00. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The stock has a market capitalization of $32.20 billion, a price-to-earnings ratio of 32.98, a PEG ratio of 1.23 and a beta of 1.45. The business’s fifty day moving average price is $73.14 and its two-hundred day moving average price is $69.20.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.34%. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.48 earnings per share. On average, equities analysts anticipate that DexCom will post 2.57 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the transaction, the insider owned 328,970 shares of the company’s stock, valued at $25,106,990.40. The trade was a 7.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,506 shares of company stock valued at $7,205,258 over the last three months. 0.28% of the stock is owned by insiders.

Institutional Trading of DexCom

Several large investors have recently made changes to their positions in DXCM. Reflection Asset Management bought a new position in DexCom in the fourth quarter valued at approximately $25,000. Ascentis Independent Advisors acquired a new position in DexCom during the first quarter valued at approximately $25,000. MCF Advisors LLC bought a new stake in DexCom during the fourth quarter worth $32,000. Wellington Grp LLC lifted its stake in DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares during the last quarter. Finally, DV Equities LLC acquired a new stake in shares of DexCom in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom News Summary

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.